November 3, 2026

To, **BSE Limited**, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	To, Listing Department, **National Stock Exchange of India Ltd**., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol**:** CAMLINFINE || Series: EQ

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

This is in continuation to our disclosure dated October 29, 2026 in relation to the conference call to discuss the Un-audited financial results of the Company for the quarter and half year ended September 30, 2026, please find enclosed herewith the investor presentation made for the aforesaid call.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI Listing Regulations.

Encl.: a/a.
Thanking You,
For Camlin Fine Sciences Limited

RAHUL SAWALE
Digitally signed by RAHUL SAWALE
Date: 2026.11.03 16:02:28 +05'30'

Rahul Sawale
Company Secretary
& VP - Legal

BLENDING
STRENGTH.
BUILDING
THE HIVE.



Camlin Fine Sciences Limited

Investor Presentation – November 2026

Safe Harbour

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Camlin Fine Sciences Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Q2 & H1FY27
Financial Highlights




Q2 & H1FY27 Financial Highlights


Revenue (Rs. In Mn)




Operational EBITDA* (Rs. In Mn)



EBITDA Margin %



PAT (Rs. In Mn)



On Consolidated Basis

*EBITDA is adjusted for FX loss

On Continued Operations

Key Operational Highlights

Financial Performance

- *Revenue came in at Rs 4,915 mn, up 9.15% YoY.*
- *Gross margin came in at 39.8% (46.5% in Q2 FY26) due to higher RM prices, limited pass-through, and liquidity issues which further impacted the EBITDA.*
- *Incurred Rs. 51 mn in maintenance expenses at the Diphenol Dahej unit, despite the facility remaining non-operational.*
- *EBITDA for the quarter stood at Rs 22.3 mn; margin 0.45%.*

Strategic Acquisition

- *Acquired additional 11% stake from the minority shareholder of Vinpai at Rs 201 mn leading to total holding at 94.82%.*

Operating Environment

- *Elevated raw material prices continue to impact the profitability of the company.*
- *Higher operating costs driven by increased freight expenses, extended transit times and longer working capital cycles.*

Segmental Highlights

- *Straights: Revenue grew by 26% on YoY basis to Rs 1,108 mn due to healthy volume growth despite local competition*
- *Blends continues its robust growth revenue grew by 25% on YoY basis*
- *Aroma: Revenue declined 41% YoY due to changeover to Methyl Vanillin during the quarter leading to lower utilization and higher unabsorbed costs*

Outlook – FY27

- *Blends: Growth momentum to continue across all geographies. Vitafor and Vinpai to stabilise.*
- *Aroma: Anticipate an improvement in volumes and realisations over the coming quarters.*
- *External Challenges: Ongoing logistics disruptions and inflationary pressures are expected to weigh on operations in the near term.*
- Board has approved the fundraise through rights issue to address liquidity challenges upto Rs 2,500 mn

On Consolidated Basis

*EBITDA is adjusted for FX loss


Segmental Highlights – Q2 & H1FY27

Specialty Ingredients	Aroma	Performance Chemicals & Others
Q2 FY27 Highlights		
STRAIGHTS ₹1,108 Revenue BLENDS ₹2,970 Revenue 8.04% EBITDA	₹472 Revenue (23.1)% EBITDA	₹1,857 Revenue (10.6)% EBITDA
H1 FY27 Highlights		
STRAIGHTS ₹2,036 Revenue BLENDS ₹6,056 Revenue 7.20% EBITDA	₹1,246 Revenue (11.5)% EBITDA	₹3,606 Revenue (6.7)% EBITDA
Key Highlights		
▪ Attractive growth markets across geographies ▪ Extensive product range – Clean label products ▪ New technologies & Functional Ingredients	▪ Margins to improve with enhanced utilization ▪ Methyl Vanillin Campaign in mid August	▪ High costs impacting the vertical ▪ Diphenol plant is under shutdown ▪ Includes Intersegment transaction


Key Focus	To Improve Margins	Working Capital Cycle	New products in functional ingredients

Operational Revenue Breakup


Specialty Ingredients (Rs. In Mn) (Straights)




Specialty Ingredients (Rs. In Mn) (Value added blends)




Total Specialty Ingredients (Rs. In Mn)



Performance Chemicals & Others (Rs. In Mn)



Aroma Ingredients (Rs. In Mn)



On Consolidated Basis

Performance Chemicals revenue includes intersegment revenue

Adjusted EBITDA

Consolidated Profit & Loss Statement

From Continuing Operations

Particulars (Rs. In Mn)	Q2 FY27	Q2 FY26	Q1 FY27	H1 FY27	H1 FY26
Revenue from Operation	**4,914.7**	**4,502.6**	**5,198.8**	10,113.4	8,579.9
Raw material consumption	2,956.9	2,411.1	3,056.8	6,013.7	4,667.9
Employee Cost	722.7	594.7	734.3	1,457.0	1,162.1
Other expenses	1,212.8	1,140.6	1,314.9	2,491.7	2,190.6
EBITDA	**22.3**	**356.3**	**92.7**	**151.0**	**559.2**
EBITDA Margins (%)	**0.45%**	**7.91%**	**1.78%**	**1.49%**	**6.52%**
Adjusted EBITDA*	**22.3**	**356.3**	**176.4**	**198.8**	**559.2**
Adjusted EBITDA Margins (%)	**0.45%**	**7.91%**	**3.39%**	**1.97%**	**6.52%**
Other Income	49.6	42.6	13.4	27.0	108.9
Depreciation	199.2	176.5	191.6	390.8	337.9
Finance cost	205.9	178.5	140.1	346.0	327.0
Exceptional Item	19.3	-	111.1	130.4	-
Share of profit / (loss) of associate	3.6	(3.6)	14.0	17.6	5.3
PBT	**(348.9)**	**40.3**	**(322.6)**	**(671.5)**	**8.5**
Tax	(68.1)	59.0	(4.6)	(72.7)	58.7
PAT	**(280.8)**	**(18.7)**	**(318.0)**	**(598.8)**	**(50.2)**

From Discontinued Operations#

PBT from discontinued operation	(16.2)	(130.8)	(18.3)	(34.4)	(205.8)
Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.3
PAT including Discontinued Operations	**(297.0)**	**(149.5)**	**(336.2)**	**(633.2)**	**(256.3)**

*EBITDA is adjusted for FX loss

Pertains to CFS Europe and CFSWL discontinued operations

Consolidated Balance Sheet

Particulars (Rs. In Mn)	Sept - 26	Mar - 26
Equity		
Equity Share Capital	192.1	192.1
Other Equity	9,528.6	10,216.7
Minority interest	(407.2)	(400.7)
Total Equity	**9,313.6**	**10,008.1**
Non-Current Liabilities		
Financial Liabilities		
Borrowings	2,653.6	3,026.1
Lease Liabilities	418.7	344.0
Other Liabilities	3.8	3.2
Provisions	75.0	72.8
Deferred Tax Liabilities (Net)	39.1	39.1
Other non-current liabilities	1.5	1.6
Total Non-Current Liabilities	**3,191.6**	**3,486.7**
Current Liabilities		
Financial Liabilities		
Borrowings	3,640.0	3,654.7
Lease Liabilities	169.5	176.1
Trade Payables	5,460.8	5,051.9
Other Financial Liabilities	592.1	617.8
Other Current Liabilities	222.1	151.9
Provisions	85.7	91.0
Current tax liabilities (Net)	1.1	0.8
Total Current Liabilities	**10,171.5**	**9,744.2**
Total Equity and Liabilities	**22,676.6**	**23,239.1**

Particulars (Rs. In Mn)	Sept - 26	Mar - 26
Non-Current assets		
Property, Plant and Equipment	5,711.2	5,692.1
Capital Work-In-Progress	237.0	328.5
Right use of assets	615.6	558.8
Goodwill	2,334.1	2,334.1
Other Intangible Assets	265.2	288.7
Intangible assets under development	0.0	0.0
Investment Property	0.0	0.0
Financial Assets		
Investments	310.1	302.6
Other Financial Assets	187.8	183.5
Deferred tax assets	1,001.6	873.8
Income Tax Assets	188.9	251.6
Other Non-Current Assets	49.9	60.2
Total Non-Current Assets	**10,901.4**	**10,874.1**
Current Assets		
Inventories	5,805.4	5,037.4
Financial Assets		
Investments	0.0	0.0
Trade Receivables	3,371.7	3,730.2
Cash and Cash Equivalents	495.0	1,085.6
Bank Balances	191.8	446.7
Loans	0.0	0.0
Other Financial Assets	340.7	578.3
Other Current Assets	1,549.2	1,465.2
Assets held for sale	21.6	21.6
Total Current Assets	**11,775.3**	**12,343.3**
Total Assets	**22,676.6**	**23,239.1**

Company Overview



Company Overview

Among Global Leaders

In the Manufacturing of Antioxidants

Offering Wide Range

of Blends & Vanillin

Preferred Partner

For Customized Shelf-Life Solutions

100+

Range of Diversified Products

Catering Diverse Industries

Food & Beverage	Animal Nutrition	Pet Food
Pharmaceuticals & Pharma Intermediates	Petrochemicals	Dyes & Pigments
Poultry & Livestock	Bio-Fuels	Aquaculture & Fishmeal
Flavours & Fragrances	Dietary Supplements	Personal Care & Home Care
Polymers	Agrochemicals	Incense Sticks

Global specialty ingredients company providing Shelf-life, Aroma and Performance solutions

80+ Countries


1,300+ Customers Worldwide

8 Global Manufacturing Facilities

7 Application Laboratories


2 R&D Centres

FY26 Revenue Mix*# ₹ 17,233 mn



Excludes CFS Europe and CFSWL discontinued operations

From Manufacturing to Global Partnerships



1

Manufacturing Backbone

India | Brazil | Mexico | France | Belgium

Scale. Reliability. Consistency.

Core production hubs anchor the network, ensuring uninterrupted supply and quality.

2

Innovation Close to Market

Americas | Europe | Asia

Co-create. Customize. Accelerate.

Application labs and R&D centres enable faster response and tailored solutions.

3

Market Reach

80+ Countries

Local relevance. Global strength.

Deep market understanding supports customer alignment across regional needs and regulations.

4

Customer Partnerships

1,300+ Customers Worldwide

Localized expertise. Agility. Trust.

Serving global leaders and emerging innovators through flexible, long-term relationships.

From continued operations

Map not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Product Highlights

	FY26 Sales%*#	Key Products	End User Industries	Key Brands
Specialty Ingredients → **Straights**	**18%**	› TBHQ › BHA › Ascorbyl palmitate (ASP)	› Pet Food › Livestock Nutrition › Food & Beverages › Fish Meal › Animal Feed Mills › Biodiesel › Aquaculture & Fishmeal › Rendering	NaSure, BIOSUS OMEGA 20, Xtendra shelf life solutions, BIOSUS DHA, Vinpai
Specialty Ingredients → **Value added Blends**	**58%**	› 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends)	› These formulations are specifically tailored to meet the diverse needs of the industry › Aim to increase focus on high-value blends and additives	
Performance Chemicals & Others	**10%**	› HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, › CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB	› Petrochemicals › Dyes & Pigments › Agrochemicals › Polymers › Pharmaceuticals › Acrylates › Electroplating › Printing Inks	Dinamic Performance Chemicals
Aroma Ingredients	**14%**	› Vanillin, Ethyl Vanillin and Vanillin ex-clove (adorr™)	› Food & Beverages › Pharmaceutical › Incense sticks › Animal Feed › Flavors & Fragrance › Agrochemicals › Personal Care	adorr sensory sciences

From continued operations

1. a. Speciality Ingredients - Straights

Key Products

TBHQ
Highly effective antioxidant for protection against oxidative degradation.

BHA
Widely used antioxidant to preserve quality and extend shelf life.

Ascorbyl Palmitate
Fat-soluble antioxidant that helps maintain color, flavor and nutritional value


Key Brands

NaSure | BIOSUS™ OMEGA 20 | Xtendra shelf life solutions | BIOSUS DHA

Key End User Industries

- Livestock Nutrition
- Pet Food
- Food & Beverages
- Biodiesel
- Animal Feed Mills
- Aquaculture & Fishmeal
- Rendering

Revenue Trend (Rs Mn)





From continued operations

1. b. Speciality Ingredients – Value Added Blends

Key Products

- 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends)
- Forward-integrated blends (TBHQ, BHA, BHT, ASP) effectively extend shelf life and prevent food/feed loss/wastage.


Key Brands

Xtendra shelf life solutions
Vinpai
BIOSUS DHA
VITAFOR

Key End User Industries

Bakery Products
Pet Food
Livestock Nutrition
Biodiesel
Animal Feed Mills
Oils & Fats
Rendering

Revenue Trend (Rs Mn)





From continued operations

Expanding Global Reach in Blends

Vitafor

Acquisition of Vitafor Invest NV

100% stake

TRANSACTION SNAPSHOT

- 100% stake acquired
- Cash consideration: €1 Mn
- Belgium-based platform

BUSINESS PROFILE

- Animal-feed ingredient manufacturer and trader
- Located near Port of Antwerp
- Established European network

STRATEGIC VALUE

- Strengthens European & African reach
- Expands Pet Food & Feed exposure
- Creates Portfolio of cross-selling opportunities

PRODUCT / APPLICATION FOCUS

- **Animal feed ingredients**
- **Nutritional additives**
- **Specialty feed solutions**

Vinpai

Strategic majority acquisition in Vinpai S.A.

Majority stake

TRANSACTION SNAPSHOT

- ~83.82% Stake acquired in Dec -2025
- Post open offer, company now holds 95.41%

BUSINESS PROFILE

- Ingredient-tech company
- Natural and functional systems
- Algae, plant, mineral & fibre-based solutions

STRATEGIC VALUE

- Deepens food-ingredient capabilities
- Adds functional blend portfolio
- Supports cross-technology innovation

PRODUCT / APPLICATION FOCUS

- **Functional ingredients**
- **Emulsifier systems**
- **Processed-cheese solutions**

Strategic Impact

Broader portfolio | New geographies | Cross-selling opportunities | Enhanced innovation capabilities

2. Aroma Chemicals

Key Products

Vanillin

Manufacture Methyl Vanillin under Vanesse™ serving multiple industries

Ethyl Vanillin

Manufacture Ethyl Vanillin under Evanil™ serving multiple industries

Vanillin Ex-Clove


Adorr™ vanillin range is manufactured inhouse ensuring consistent quality, reliable supply, and complete traceability.



Key End User Industries

Food & Beverages | Flavours & Fragrance | Pharmaceuticals | Incense Sticks | Animal Feed | Agrochemicals | Livestock Nutrition

Revenue Trend (Rs Mn)



Key Brands

adorr VANILLIN US NATURAL

adorr VANILLIN premium

adorr VANILLIN free flow

adorr VANILLIN SOLUTIONS

adorr ETHYL VANILLIN premium

INTENSE GREEN

From continued operations

3. Performance Chemicals & Others

Key Products

HQ Derivatives

- Chloranil
- MEHQ
- HQEE
- TBHQ
- PDMB
- CME

Catechol Derivatives

- 4 TBC
- Guethol
- Veratrole
- Guaiacol
- 1, 2MDB



Key End User Industries

Petrochemicals | Dyes & Pigments | Acrylates | Agrochemicals

Electroplating | Pharmaceuticals | Polymers | Printing Inks





Key Brands

Dinamic Performance Chemicals

From continued operations

Strategic Focus Areas across Segments

1. Speciality Ingredients (Straights + Blends + Vitafor + Vinpai)

AMEA Region

- **Portfolio Expansion -** Expand Xtendra®, NaSure®, and Enzentia® across food, functional ingredients, and animal nutrition
- **Domestic Market Expansion** – Strengthen poultry and scale aquaculture
- **Export Growth** - Expand internationally, especially in the Middle East.
- **Growth & Market Positioning** - Outpace industry growth through innovation and wider reach

America Region

- **Speciality Solutions -** Scale Xtendra®, NaSure®, Ezential® and Vinpai across food markets
- **Animal Nutrition Growth** – Expand performance nutrition, gut health and Vitafor™ solutions
- **Biodiesel Expansion** - Grow Brazil market share through scale and innovation.
- **Market Development** - Deepen customer partnerships and enter aquaculture and water treatment.

Europe Region

- Expansion into high-potential markets
- Increased adoption of farm-level performance solutions
- Product Development with increased focus on ruminant nutrition
- Continued integration with global Animal Nutrition platform

2. Aroma Chemicals

- Deepened partnerships with key accounts
- Ongoing efforts to strengthen presence in core geographies
- Expansion with select high value customers across other regions
- Continued focus on quality, reliability and service excellence
- Optimizing supply chain and cost structures

3. Performance Chemicals & Others

- Accelerate towards Speciality applications
- Expand presence in high-performance segments to reduce dependence on commodity price cycles
- Building on Diphenol platform and leveraging R&D capabilities



From continued operations

ESG

Environmental

- Transitioned from periodic monitoring to real-time environmental visibility through online installations, infrastructure upgrades
- Undertook comprehensive thermal insulation program to minimize heat loss and optimize energy

Social

- Completely renovated the Occupational Health Centre (OHC) to strengthen employee healthcare infrastructure.
- Enhanced medical surveillance and wellness support for employees.
- Successfully completed SEDEX audits, validating responsible workplace practices
- Continued investment in workplace health, safety and inclusivity, particularly across manufacturing plants.

Governance

- Diverse and experienced Board composition spanning technical and commercial expertise.
- Regular, solutions-focused Board sessions to refine corporate policies and strategic priorities.
- Strengthened risk-management practices aligned with the Company's ESG objectives.
- Progressed the FY2025–26 Global Reporting Initiative (GRI) assignment to strengthen sustainability reporting.



Board of Directors



Ashish Dandekar
Chairman & Managing Director

- Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing
- Holds a BA in Economics and Management studies from Temple University, USA



Nirmal Momaya
Managing Director

- Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy
- He has been instrumental in providing strategic guidance & direction to the company on all significant business matters



Arjun Dukane
Executive Director-Technical

- Chemical Engineer with over three decades of experience in the chemical industry
- Has been associated with CFS for more than 15 years



Harsha Raghavan
Non-Executive Non-Independent Director

- Managing Partner of Convergent Finance LLP and ex-founding MD & CEO of Fairbridge Capital (a Fairfax Company)
- Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley



Anagha Dandekar
Non-Executive Non-Independent Director

- President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories
- Holds an MBA in Finance from the University of South Carolina, USA



Jens Van Nieuwenborgh
Non-Executive Non-Independent Director

- Board member of several companies across India and Europe, with extensive experience in business administration, finance, and operations
- Holds an MBA from Harvard University and a Master's in Science from Ghent University, Belgium.



Amol Shah
Independent Director

- Managing Director of the MJ Group with over three decades of experience covering human healthcare, F&F compounds, plant protection, and water treatment chemicals
- Holds an MBA from the University of Southern California and a Bachelor's in Engineering from the University of Kent



Mahabaleshwar Palekar
Independent Director

- Over three decades of experience with corporates in India and MNCs
- Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India



Joseph Conrad D'souza
Independent Director

- Erstwhile Member of Executive Management and Ex-Chief Investor Relations Officer of HDFC Ltd
- Holds an M.com from Mumbai University and an MBA from South Gujarat University



Atul Pradhan*
Independent Director

- Former Head of Management Consulting at KPMG India, with extensive experience in strategy, business transformation, corporate governance and M&A.
- Has led 100+ consulting engagements and served on CII and FICCI national committees
- Served as Independent Director at Camlin Fine Sciences (2014–2021).



Abeezar Faizullabhoy
Independent Director

- Senior Partner at CMS Indus Law (Solicitors & Advocates) – Mumbai and ex-partner of J Sagar Associates
- Holds Bachelor of Law from University of Mumbai and a Qualified Solicitor from Bombay incorporated law society
- Was previously on Board of CFS for 13 years till 2019, His immense experience in the Corporate commercial, litigation, M&A



Radhika Dudhat
Independent Director

- Over three decades of experience with corporates in India and MNCs
- Partner with Shardul Amarchand Mangaldas & Co. and has worked on a wide range of transactional, regulatory and legal risk management advisory
- Holds degrees in Life Sciences and Law from the University of Bombay, with postgraduate studies at Cambridge and Harvard.

*Pradip Kanakia ceased as Independent Director upon completion of his tenure on October 18, 2026, while Atul Pradhan was appointed as Independent Director effective September 11, 2026.

Senior Management Team


Ashish Dandekar **Chairman & Managing Director**	› Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA
Nirmal Momaya ***Managing Director***	› Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters
Arjun Dukane ***Executive Director- Technical***	› Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years
Santosh Parab ***President – Strategy and Global CFO***	› Over three decades of experience working auditing profession › Previously worked at renowned Indian accounting firm › Qualified Chartered Accountant with a Bachelor's degree in commerce › Associated with CFS for more than 10 years
Pankaj Pandey ***Chief Financial Officer***	› Over two decades of experience across finance & accounts › Qualified Chartered Accountant and cleared CISA › Previously worked with Transasia Bio Medicals, Sun Pharmaceutical Industries, KPMG, Glenmark Pharmaceuticals, Larsen & Toubro
Nilesh Jadhav ***Chief Operating Officer***	› Chemical Engineer with around three decades of experience in the chemical industry including heading multilocational manufacturing sites › Previously worked at Balaji Amines, Deepak Fertilizers & Petrochemicals, Essar Refinery & Schenectady › Executive Management from IIM Bangalore and Piping Engineering from IIT Powai
Eric Santos ***Vice President – Aroma Ingredients***	› Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. › Holds a Bachelor's degree in chemistry
Jose Arturo Paulin ***Head – Mexico operations***	› Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) › Previously worked at Trouw Nutrition and Kemin Inc in Mexico › Qualifed agriculture engineer
Jennifer Igou ***Head – USA operations***	› Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids › Previously worked at Kemin Inc. USA & FMC › Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine

Historical Financial Highlights




Historical Financial Highlights


Revenue (Rs. In Mn)



EBITDA (Rs. In Mn)




PAT (Rs. In Mn)




Continued Operation

Discontinued Operation

Net Debt to Equity (x)




Net Debt to EBITDA (x)




On Consolidated Basis

Operational Revenue Break-up


Specialty Ingredients (Rs. In Mn) (Straights)




Specialty Ingredients (Rs. In Mn) (Value added blends)




Total Specialty Ingredients (Rs. In Mn)




Performance Chemicals & Others (Rs. In Mn)#



Aroma Ingredients (Rs. In Mn)



Total Revenue Breakup (%)*



Specialty Ingredients (Straights) | Specialty Ingredients (Value Added Blends) | Performance Chemicals | Aroma Ingredients

On Consolidated Basis

*Excluding Other Products

FY24, FY25 & FY26 figures excludes Diphenol CFS Europe and entire CFSWL discontinued operations

#Performance Chemicals exclude intersegment revenue

Thank You !

Camlin Fine Sciences Ltd.
CIN – L74100MH1993PLCO75361
Santosh Parab - President – Strategy and Global CFO
Email – santosh.parab@camlinfs.com
www.camlinfs.com

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285
Shrikant Sangani / Shaily Patwa
Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net
Mobile No – 9619595686 / 9819494608
www.sgapl.net

